Search Results

1 - 10 of 76 items :

  • "peripheral neuropathy" x
Clear All

.L., MAMALI I., MOUTSOPOULOS H.M., TZIOUFAS A.G. et al. Peripheral neuropathies in Sjögren’s syndrome: A critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012; 39 :27–33. 5. MARGARETTEN M. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018; 56 :99–105. 6. DELALANDE S., DE SEZE J., FAUCHAIS A.-L., HACHULLA E., STOJKOVIC T., FERRIBY D. et al. Neurologic manifestations in primary Sjögren syndrome. Medicine (Baltimore). 2004; 83 :280–91. 7. MOROZUMI S., KAWAGASHIRA Y., IIJIMA M., KOIKE H., HATTORI N., KATSUNO M

References 1. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med. 1999; 107 (2B):2S-8S. 2. Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med. 1999; 107 (2B):9S-16S. 3. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004; 27(6):1458-86. 4. Cohen JA, Jeffers BW, Faldut D, Marcoux M, Schrier RW. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Muscle Nerve. 1998; 21(1):72-80. 5. Di Nardo

References 1. Dub JJ, Campbell RK, Setter SM, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 61: 160-173, 2004. 2. Hare JA, Abuaisha F, Geoghegan M. Prevalence and forms of neuropathic morbidity in 800 diabetics. Ir J Med Sci 163: 132-135, 1994. 3. Bhadada SK, Sahay RK, Jyotsna VP, Agrawal JK. Diabetic neuropathy: current concepts. J Indian Acad Clin Med 2: 305-318, 2001. 4. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 27: 1458-1486, 2004. 5. Harati Y. Diabetic peripheral neuropathies

A, Fernando D, Boulton AJ. Current perception thresholds: a new, quick and reproducible method for the assessment of peripheral neuropathy in diabetes mellitus. Diabetologia 32: 724-728, 1989. 21. 22. Tavakoli M, Quattrini C, Abbott C et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 33: 1792-1797, 2010. 23. Midena E, Brugin E, Ghirlando A, Sommavilla M, Avogaro A. Corneal diabetic neuropathy: a confocal microscopy study. J Refract Surg 22(9 Suppl): S1047

R eferences 1. Callaghan BC, Cheng HT, Stables CL et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 11(6): 521-34, 2012. 2. Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. Journal of rehabilitation medicine 42(4): 289-95, 2010. 3. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes/Metabolism Research and Reviews 24(1): 52-57, 2008. 4. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ

-peptide. J Neurol Sci 220: 133-6, 2004. 5. Höliner I, Haslinger V, Lütschg J et al. Validity of the neurological examination in diagnosing diabetic peripheral neuropathy. Pediatr Neurol 49: 171-177, 2013. 6. Jack MM, Ryals J, Wright DE. Protection from diabetes-induced peripheral sensory neuropathy—a role for elevated glyoxalase I? Exp Neurol 234: 62–69, 2012. 7. Sytze Van Dam P, Cotter M, Bravenboer B, Cameron NE. Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms. Eur J Pharmacol 719: 180-186, 2013. 8. De Visser A, Hemming A, Yang C et al

, Buechler, P. Pellikka, J. S. Newman,. A 45 YEAR OLD MAN WITH FEVER, WEIGHT LOSS, ANEMIA AND PERIPHERAL NEUROPATHY. Journal of Hospital Medicine. 2014(9).

cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain. 2007; 130:1076-88. 4. McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005; 18:305-13. 10.1016/j.nbd.2004.09.013 5. Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon MS, Kaube H, et al. Repair capacity for platinum- DNA adducts determines the severity of cisplatininduced peripheral neuropathy. J Neurosci. 2007; 27: 9451-7. 10.1523/JNEUROSCI

factor in diabetic vascular complications. Kidney Int Suppl. 2000;77:S113-9. DOI: 10.1046/j.1523-1755.2000.07718.x 13. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst. 2004;9:26-53. DOI: 10.1111/j.1085-9489.2004.09105.x 14. Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B, et al. VEGF gene polymorphism association with diabetic neuropathy.Mol Biol Rep. 2010;37:3625-30. DOI: 10.1007/ s11033-010-0013-6 15. Quattrini C, Jeziorska M, Boulton AJ, Malik RA. Reduced

Cisplatin-induced non-convulsive posterior reversible encephalopathy syndrome in a 41-year-old woman with metastatic malignant melanoma

Background. Cisplatin, a widely used antineoplastic agent usually induces peripheral neuropathy, but can rarely also complicate with encephalopathy, with or without seizures.

Case report. We report a case of a young patient with metastatic malignant melanoma with signs and symptoms of cisplatin-induced non-convulsive posterior reversible encephalopaty syndrome. Within the days shortly after the first cycle of cisplatin based chemotherapy the patient suffered from nausea, vomitus, headache, severe pain at the site of sub-cutaneous metastases and confusion. She later experienced somnolence, cortical blindness and aphasia, but without epileptic seizures.

Conclusions. Cisplatin is an effective chemotherapeutic drug but also very toxic one and physicians using it must also be aware of possible encephalopathy.